Clinical trials: Cognitive Decline, Mild
Alzheimer Disease
A Study to Assess Safety and Target Engagement of E2814 in Participants With Mild to Moderate Cognitive Impairment Due to Dominantly Inherited Alzheimer's Disease
The primary objective of the study is to assess the safety and tolerability of intravenous (IV) infusions of E2814 in participants with dominantly inherited Alzheimer's disease (DIAD), and to evaluate target engagement (TE) of…
- Trial name
- NCT04971733
- Testing
- E2814
- Where
- 3 sites in United States, United Kingdom
- Volunteers
- 8 people
- Sponsor
- Eisai Inc.
Alzheimer Disease
A Study of LY3002813 in Participants With Memory Damage Due to Alzheimer's Disease (AD) or AD
The study will evaluate the effect of LY3002813 on brain scans. The study will evaluate the safety of LY3002813 by looking at adverse events (side effects). The study will also look at the effect the body has on LY3002813.
- Trial name
- NCT02624778
- Testing
- LY3002813
- Where
- 9 sites in United States, Japan
- Volunteers
- 61 people
- Sponsor
- Eli Lilly and Company
Prostate Cancer, Mild Cognitive Impairment
PET Imaging in MCI Following ADT for PCa
Mild cognitive impairment (MCI) with ageing is thought in part to be related to reduced serum sex hormones which is well-recognized, especially in females, but poorly understood.
- Trial name
- NCT02061345
- Where
- United Kingdom
- Volunteers
- 11 people
- Sponsor
- Imperial College London
Mild Cognitive Impairment, Alzheimer's Disease
Minocycline in Patients With Alzheimer's Disease
Cognitively normal individuals, patients with Mild Cognitive Impairment (MCI) or Alzheimer's Disease (AD) will undergo clinical screening, neuropsychological tests, blood and urine analyses, quantitative magnetic resonance…
- Trial name
- NCT01463384
- Testing
- Minocycline
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Huntington Medical Research Institutes
Mild Cognitive Impairment
Intervention to Reduce Sedentary Time
The purpose of this study is to determine whether the researchers can help people change the amount of time they spend in sitting activities and whether this change might improve health outcomes.
- Trial name
- ReST-MCI (NCT02878486)
- Testing
- Jawbone Up, Physical Activity Education, ActivPAL
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Kansas Medical Center
Mild Cognitive Impairment, Alzheimer's Disease
Promoting Adaptive Neuroplasticity in Mild Cognitive Impairment
The aging US population threatens to overwhelm our healthcare infrastructure, especially since the rate of Alzheimer's disease (AD) alone is expected to triple in the coming decades.
- Trial name
- NCT02155946
- Testing
- Transcranial direct current stimulation (tDCS) Soterix Medical Inc. tDCS unit
- Where
- United States
- Volunteers
- 107 people
- Sponsor
- VA Office of Research and Development
Alzheimer's Disease, Cognitive Impairment
Effect of EGb761® on Brain Glucose Metabolism in Three Groups of Elderly Defined by Cognitive Functions
The aim of the study is to evaluate the effect of EGb761®, in comparison to placebo, on cerebral glucose metabolism, in three groups of elderly patients: newly diagnosed mild Alzheimer's disease (AD), memory complaint patients…
- Trial name
- NCT00814346
- Testing
- EGb761®
- Where
- 8 sites in France
- Volunteers
- 49 people
- Sponsor
- Ipsen
Mild Cognitive Impairment
Effects Multimodal Mind and Body Approach for MCI
The aim of this application is to develop a computer-based multimodal mind and body approach (CMMBA) for mild cognitive impairment (MCI).
- Trial name
- NCT06814483
- Testing
- Experimental: A computer-based multimodal mind and body approach (cbMMBA), A standard cognitive training group
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Massachusetts General Hospital
Mild Cognitive Impairment
Efficacy and Safety Study of Shenwu Capsule
The purpose of this phase III study is to further evaluate the effects of shenwu capsule, a traditional Chinese herbal medicine, on cognition, function and memory in patients with amnestic mild cognitive impairment (MCI) who are…
- Trial name
- NCT01451749
- Testing
- Shenwu Capsule, Donepezil
- Where
- China
- Volunteers
- 324 people
- Sponsor
- North China Pharmaceutical Group Corporation
Cognitive Dysfunction, Alzheimer's Disease
A Study of Aducanumab in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease Dementia to Evaluate the Safety of Continued Dosing in Participants With Asymptomatic Amyloid-Related Imaging Abnormalities
The primary objective of the study is to assess the safety impact of continuing aducanumab dosing in asymptomatic Amyloid-related Imaging Abnormalities (ARIA) in participants with mild cognitive impairment (MCI) due to…
- Trial name
- EVOLVE (NCT03639987)
- Testing
- Aducanumab
- Where
- 22 sites in United States
- Volunteers
- 52 people
- Sponsor
- Biogen
Alzheimer's Disease, Mild Cognitive Impairment
Study of Nasal Insulin to Fight Forgetfulness - Long-acting Insulin Detemir - 120 Days (SL120)
The study will examine the effects of intranasally administered long-acting insulin detemir on cognition in persons with Alzheimer's disease (AD) or amnestic mild cognitive impairment (aMCI).
- Trial name
- SL120 (NCT01595646)
- Testing
- Saline, Insulin detemir, Insulin
- Where
- 2 sites in United States
- Volunteers
- 37 people
- Sponsor
- Wake Forest University Health Sciences
Obstructive Sleep Apnea, Mild Cognitive Impairment
Mild Cognitive Impairment and Obstructive Sleep Apnea
Obstructive sleep apnea (OSA) has been linked to increased risk for Alzheimer's disease (AD), but little prospective evidence exists on the effects of OSA treatment in preclinical AD.
- Trial name
- MEMORIES (NCT01482351)
- Testing
- CPAP adherence intervention, Attention control intervention
- Where
- 3 sites in United States
- Volunteers
- 54 people
- Sponsor
- George Mason University
Mild Cognitive Impairment (MCI), Alzheimer Disease
A Study of Donanemab (LY3002813) Compared With Aducanumab in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 4)
The main purpose of this study is to compare donanemab to aducanumab on brain amyloid plaque clearance in participants with early symptomatic Alzheimer's Disease (AD).
- Trial name
- NCT05108922
- Testing
- Donanemab, Aducanumab
- Where
- 31 sites in United States
- Volunteers
- 148 people
- Sponsor
- Eli Lilly and Company
Alzheimer Disease
A Study of LY3002813 in Participants With Alzheimer's Disease
The study will evaluate the safety of LY3002813 by looking at adverse events. The study will also look at the effect the body has on LY3002813.
- Trial name
- NCT01837641
- Testing
- LY3002813-IV, LY3002813-SC
- Where
- 6 sites in United States, Japan
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Adherence, Treatment, Retention
KNA Proof-of-Concept
The intervention program proof-of-concept was assessed as a single-arm, within-subjects clinical study with a target enrollment of 10 participants with possible or probable amnestic MCI.
- Conditions
- Adherence, Treatment, Retention, Cognitive Impairment, Mild
- Trial name
- NCT04968041
- Testing
- Motivational Interviewing-Cognitive Behavioral Therapy Ketogenic Nutrition Adherence Program
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Florida State University
Alzheimer Disease, Mild Cognitive Impairment
Brain Energy Metabolism and Sleep in Adults
The three primary goals of this pilot will be followed by a secondary goal to test if dental intervention improves brain health in terms of sleep and cognition. The primary and secondary goals are 1.
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Cognitive Change, Energy Metabolism
- Trial name
- NCT03929302
- Testing
- MyTAP oral appliance plus mouth shield
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- The University of Texas at Dallas
Mild Cognitive Impairment (MCI)
Preventing Cognitive Decline in African Americans With Mild Cognitive Impairment
The goal of this study is to determine whether increasing participation in cognitive, physical, and/or social activities prevents cognitive decline in older African Americans (AAs) with Mild Cognitive Impairment (MCI).
- Trial name
- NCT01299766
- Testing
- Behavioral Activation (BA), Supportive Therapy (ST)
- Where
- United States
- Volunteers
- 221 people
- Sponsor
- Thomas Jefferson University
Myelodysplastic Syndrome, Effects of Chemotherapy
Electrophysiological Biomarkers of Chemotherapy-related Cognitive Impairment and Recovery
Broadly speaking, the goal of this study is to better understand the influence of chemotherapy treatment on the cognitive and neural mechanisms underlying human behavior.
- Conditions
- Myelodysplastic Syndrome, Effects of Chemotherapy, Mild Cognitive Impairment, Multiple Myeloma
- Trial name
- Chemobrain (NCT02767388)
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- University of Nebraska
Posttraumatic Stress Disorder, Depression
A Policy Relevant US Trauma Care System Pragmatic Trial for PTSD and Comorbidity
The overarching goal of this UH2-UH3 proposal is to work with the NIH Health Care Systems Research Collaboratory to develop and implement a large scale, cluster randomized pragmatic clinical trial demonstration project that…
- Conditions
- Posttraumatic Stress Disorder, Depression, Alcohol-Related Disorders, Suicidal Ideation
- Trial name
- TSOS6 (NCT02655354)
- Testing
- Motivational Interviewing, Cognitive Behavioral Therapy Elements, Care Management
- Where
- 24 sites in United States
- Volunteers
- 635 people
- Sponsor
- University of Washington
Healthy Volunteers
A Study of LY2886721 in Healthy Participants
The purpose of this phase I study in healthy participants will be to evaluate the safety and tolerability of LY2886721 single and multiple doses, to evaluate how the body handles the drug, and to evaluate the drug's effect on the…
- Trial name
- NCT01534273
- Testing
- LY2886721
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company